Gastrointestinal safety evaluation of semaglutide for the treatment of type 2 diabetes mellitus: A meta-analysis.

Huang X, Wu M, Lin J, Mou L, Zhang Y, Jiang J

Medicine1 May 2024Cited by 3 (Europe PMC)

PMID38787986PMCIDPMC11124640DOI10.1097/md.0000000000038236PepBankPUB-38787986

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanSystematic reviewSafety outcome
In a meta-analysis of randomized trials in type 2 diabetes, gastrointestinal adverse events were more frequent with semaglutide than with control across all dose groups.
In plain wordsIn people with type 2 diabetes, semaglutide caused more stomach and bowel side effects than control treatment across all doses.
Peptide
Semaglutide
Outcome
IncreaseOverall GI adverse events versus control
Study
n: not reported in source
Comparator
Control group
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
The outcomes unveiled a noteworthy rise in the collective occurrence of GIAEs across all dosage groups of semaglutide in comparison with the control group (P < .05).
1 context sentence(design, population, supporting numbers)
Summary · context
We systematically searched 4 independent databases for randomized controlled trials investigating the application of semaglutide in managing type 2 diabetes mellitus.
Report a problemFND-3878798601
02HumanSystematic reviewSafety outcome
In a meta-analysis of randomized trials in type 2 diabetes, semaglutide had a higher rate of gastrointestinal adverse events than placebo.
In plain wordsIn people with type 2 diabetes, semaglutide caused more stomach and bowel side effects than placebo.
Peptide
Semaglutide
Outcome
IncreaseGI adverse events versus placebo
Study
n: not reported in source
Comparator
Placebo
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
Upon further analysis, it was observed that semaglutide showed a heightened occurrence of GIAEs in contrast to the placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
We systematically searched 4 independent databases for randomized controlled trials investigating the application of semaglutide in managing type 2 diabetes mellitus.
Report a problemFND-3878798602
03HumanSystematic reviewSafety outcome
In a meta-analysis of randomized trials in type 2 diabetes, the rate of gastrointestinal adverse events with semaglutide did not differ significantly from that with reduced conventional doses.
In plain wordsIn people with type 2 diabetes, stomach and bowel side effects with semaglutide did not differ significantly from those with lower doses.
Peptide
Semaglutide
Outcome
No significant changeGI adverse events versus reduced conventional doses
Study
n: not reported in source
Comparator
Reduced conventional doses of semaglutide
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
However, statistically significant distinction was not observed when compared to the reduction of conventional doses or the transition to other types of glucagon-like peptide-1 receptor agonist.
1 context sentence(design, population, supporting numbers)
Summary · context
We systematically searched 4 independent databases for randomized controlled trials investigating the application of semaglutide in managing type 2 diabetes mellitus.
Report a problemFND-3878798603
04HumanSystematic reviewSafety outcome
In a meta-analysis of randomized trials in type 2 diabetes, the rate of gastrointestinal adverse events with semaglutide did not differ significantly from that with other GLP-1 receptor agonists.
In plain wordsIn people with type 2 diabetes, stomach and bowel side effects with semaglutide did not differ significantly from those with other GLP-1 drugs.
Peptide
Semaglutide
Outcome
No significant changeGI adverse events versus other GLP-1 receptor agonists
Study
n: not reported in source
Comparator
Other GLP-1 receptor agonists
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
However, statistically significant distinction was not observed when compared to the reduction of conventional doses or the transition to other types of glucagon-like peptide-1 receptor agonist.
1 context sentence(design, population, supporting numbers)
Summary · context
We systematically searched 4 independent databases for randomized controlled trials investigating the application of semaglutide in managing type 2 diabetes mellitus.
Report a problemFND-3878798604
05HumanSystematic reviewSafety outcome
In a meta-analysis of randomized trials in type 2 diabetes, treatment with semaglutide for more than 30 weeks was associated with some decrease in the incidence of gastrointestinal events.
In plain wordsIn people with type 2 diabetes, longer semaglutide treatment was linked to somewhat fewer stomach and bowel side effects.
Peptide
Semaglutide
Outcome
DecreaseGI adverse events by treatment duration
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
Additionally, an extended treatment duration with semaglutide (>30 weeks) demonstrated an association with a certain degree of decrease in the incidence of gastrointestinal events.
1 context sentence(design, population, supporting numbers)
Summary · context
We systematically searched 4 independent databases for randomized controlled trials investigating the application of semaglutide in managing type 2 diabetes mellitus.
Report a problemFND-3878798605

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.